Ensysce Biosciences, Inc.ENSCEarnings & Financial Report
Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm specializing in developing innovative prodrug therapies for pain management and oncology indications. Its proprietary platform is designed to reduce opioid abuse risks while enhancing treatment efficacy, targeting global healthcare and pharmaceutical markets with a focus on unmet clinical needs.
Revenue
$3.4M
Gross Profit
N/A
Operating Profit
$644.7K
Net Profit
$661.8K
Gross Margin
N/A
Operating Margin
18.9%
Net Margin
19.4%
YoY Growth
685.3%
EPS
$1.00
Ensysce Biosciences, Inc. Q3 FY2024 Financial Summary
Ensysce Biosciences, Inc. reported revenue of $3.4M (up 685.3% YoY) for Q3 FY2024, with a net profit of $661.8K (up 124.6% YoY) (19.4% margin).
Key Financial Metrics
| Total Revenue | $3.4M |
|---|---|
| Net Profit | $661.8K |
| Gross Margin | N/A |
| Operating Margin | 18.9% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Ensysce Biosciences, Inc. Q3 FY2024 revenue of $3.4M breaks down across 2 segments, led by Other at $1.8M (52.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $1.8M | 52.1% |
| TAAPOUD | $1.6M | 47.9% |
Ensysce Biosciences, Inc. Annual Revenue by Year
Ensysce Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $5.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $5.1M |
| 2023 | $2.2M |
| 2022 | $2.5M |
Ensysce Biosciences, Inc. Quarterly Revenue & Net Profit History
Ensysce Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.9M | +44.4% | $-2.8M | -147.0% |
| Q3 FY2025 | $493.1K | -85.6% | $-3.7M | -756.3% |
| Q2 FY2025 | $1.4M | +654.4% | $-1.7M | -126.4% |
| Q1 FY2025 | $1.3M | +331.7% | $-1.9M | -147.4% |
| Q4 FY2024 | $1.3M | +153.1% | $-3.6M | -273.4% |
| Q3 FY2024 | $3.4M | +685.3% | $661.8K | 19.4% |
| Q4 FY2023 | $515.0K | -64.1% | $-3.5M | -680.4% |
| Q3 FY2023 | $435.4K | +55.9% | $-2.7M | -618.0% |
Income Statement
| Q3 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $435380 | $515033 | $3.4M | $1.3M | $1.3M | $1.4M | $493104 | $1.9M |
| YoY Growth | 55.9% | -64.1% | 685.3% | 153.1% | 331.7% | 654.4% | -85.6% | 44.4% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $3.2M | $2.7M | $9.4M | $5.6M | $4.6M | $5.6M | $3.2M | $7.5M |
| Liabilities | $2.1M | $3.4M | $2.8M | $2.2M | $1.9M | $2.5M | $2.3M | $4.6M |
| Equity | $1.5M | $-322858 | $6.9M | $3.7M | $3.0M | $3.4M | $1.2M | $3.2M |
Cash Flow
| Q3 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.3M | $-1.8M | $-1.0M | $-764090 | $-1.7M | $-2.7M | $-1.9M | $-1.5M |